Eltrombopag-13C4

Eltrombopag-13C4 (SB-497115-13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells[1][2][3][4][5].

Product Specifications

CAS Number

[1217230-31-3]

Product Name Alternative

SB-497115-13C4

UNSPSC

12352005

Target

Apoptosis; Bacterial; Thrombopoietin Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/eltrombopag-13c4.html

Purity

97.89

Solubility

10 mM in DMSO|DMF : ≥ 1mg/mL|DMSO : ≥ 20mg/mL|Ethanol : ≥ 0.1mg/mL

Smiles

O=[13C](/[13C]1=N/NC(C=CC=C2C3=CC(C(O)=O)=CC=C3)=C2O)N(C(C=C4)=CC(C)=C4C)N=[13C]1[13CH3]

Molecular Formula

C21 13C4H22N4O4

Molecular Weight

446.44

References & Citations

[1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27 (2) :424-30.|[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33 (1) :85-93.|[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel) . 2021 Nov 9;10 (11) :1372.|[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47 (5) :1696-702.